Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.

ctDNA-positive rate was 57% (260/460) at baseline and fell to 22% (94/422) after neoadjuvant treatment, pre-cystectomy. Clearance from baseline to pre-cystectomy was 41% with durvalumab plus NAC vs 31% with NAC alone. Pre-cystectomy ctDNA-positive status was associated with non-pCR in 97% (86/89). Event-free survival benefit of perioperative durvalumab was observed in both baseline ctDNA-positive and ctDNA-negative groups. Post-cystectomy ctDNA-positive rate was 9% (31/345).

ASCO Annual Meeting 2025